ALAMEDA, Calif. , May 6, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2026.
Barchart Research What to Expect from PEN Earnings PEN Generated May 5, 2026 Current Price $323.86 EPS Estimate $$1.11 Consensus Rating Hold Average Move 8.04% Penumbra's First Quarter Without Guidance...
Barchart Research What to Expect from PEN Earnings PEN Generated April 28, 2026 Current Price $325.99 EPS Estimate $$1.11 Consensus Rating Hold Average Move 8.04% Penumbra's Thrombectomy Momentum: The...
1 Mid-Cap Stock on Our Buy List and 2 We Ignore
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Penumbra , Inc....
Penumbra (NYSE:PEN): Strongest Q4 Results from the Medical Devices & Supplies - Cardiology, Neurology, Vascular Group
1 Profitable Stock on Our Buy List and 2 We Brush Off
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.